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Background: Artesunate plus sulphadoxine-pyrimethamine (AS+SP) is now first-line treatment for Plasmodium
falciparum infection in several south Asian countries, including Afghanistan. Molecular studies provide a sensitive
means to investigate the current state of drug susceptibility to the SP component, and can also provide
information on the likely efficacy of other potential forms of artemisinin-combination therapy.
Methods: During the years 2007 to 2010, 120 blood spots from patients with P. falciparum malaria were obtained
in four provinces of Afghanistan. PCR-based methods were used to detect drug-resistance mutations in dhfr, dhps,
pfcrt and pfmdr1, as well as to determine copy number of pfmdr1.
Results: The majority (95.5%) of infections had a double mutation in the dhfr gene (C59R, S108N); no mutations at
dhfr positions 16, 51 or 164 were seen. Most isolates were wild type across the dhps gene, but five isolates from the
provinces of Kunar and Nangarhar in eastern Afghanistan had the triple mutation A437G / K540E / A581G; all five
cases were successfully treated with three receiving AS+SP and two receiving dihydroartemisinin-piperaquine. All
isolates showed the pfcrt SVNMT chloroquine resistance haplotype. Five of 79 isolates had the pfmdr1 N86Y
mutation, while 52 had pfmdr1 Y184F; positions 1034, 1042 and 1246 were wild type in all isolates. The pfmdr1
gene was not amplified in any sample.
Conclusions: This study indicates that shortly after the adoption of AS+SP as first-line treatment in Afghanistan,
most parasites had a double mutation haplotype in dhfr, and a small number of isolates from eastern Afghanistan
harboured a triple mutation haplotype in dhps. The impact of these mutations on the efficacy of AS+SP remains to
be assessed in significant numbers of patients, but these results are clearly concerning since they suggest a higher
degree of SP resistance than previously detected. Further focused molecular and clinical studies in this region are
urgently required.
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Malaria remains a significant health concern in Afghanistan
with ongoing transmission of both Plasmodium falciparum
and Plasmodium vivax in many northern and eastern prov-
inces [1-3]. Resistance of P. falciparum to chloroquine in
Afghanistan was first apparent in the late 1980s [4], and by
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reproduction in any medium, provided the orin eastern Afghanistan was extremely low [5]; neither did
the addition of artesunate to amodiaquine provide sufficient
efficacy, being associated with an adequate clinical and
parasitological response rate of only 72% [5]. During this
period the efficacy of sulphadoxine-pyrimethamine (SP)
was relatively preserved, with cure rates of 77-92% reported
in eastern [5] and northern Afghanistan [6] as well as adja-
cent areas of Pakistan [7] (only the last study was able to
correct for re-infection by PCR). Comparable success rates
with SP were also noted in south-east Iran, although here
there was also evidence of clinical resistance in a small
number of parasites, associated with target mutations intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Numbers of isolates carrying mutations at key
positions in four anti-malarial resistance genes
Gene Mutation examined N Mutated (%)
DHFR A16V 44 0 (0)
N51I 44 0 (0)
C59R 44 42 (95.5)
S108N 44 44 (100)
I164L 44 0 (0)
DHPS S436A 60 0 (0)
A437G/S 57 8* (14)
K540E 60 5 (8.3)
A581G 60 8 (13.3)
A613S 60 0 (0)
PFMDR1 N86Y 79 5 (6)
Y184F 79 52 (65.8)
S1034C 85 0 (0)
N1042D 80 0 (0)
D1246Y 43 0 (0)
Copy number** 62 0 (0)
PFCRT K76T 49 49 (100)
*7 isolates had A437G and1 isolate had A437S; **Mutated = amplified.
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(dhps) [8]. The relative preservation of SP efficacy, along
with increasing evidence for long-term benefits of arte-
misinin combination therapy (ACT), indicated that
artesunate combined with sulphadoxine-pyrimethamine
(AS+SP) would prove an effective regimen across the
region. AS+SP became first-line treatment for P. falcip-
arum infection in several south Asian countries, be-
coming first-line treatment in Afghanistan in 2004,
followed by Iran (2006) and India and Pakistan (2007).
Molecular studies probably provide the earliest warn-
ing signs of resistance to the SP component of AS+SP
[9,10]. For operational reasons, until recently there have
been no molecular data on P. falciparum SP resistance
markers in isolates obtained within the borders of
Afghanistan. Indirect indicators of the likely situation in
Afghanistan have been obtained through studies in areas
of Pakistan with high influx rates of refugees from
Afghanistan. Work in this context, undertaken in 2002–
3, indicated high efficacy for AS+SP with no evidence of
worsening resistance in terms of molecular markers
for SP [7].
Mutations in the P. falciparum chloroquine resistance
transporter gene (pfcrt) and multidrug resistance gene 1
(pfmdr1), as well as amplification of pfmdr1, are associ-
ated with altered responses to a variety of antimalarials,
including chloroquine as well as the ACT partner drugs
amodiaquine, mefloquine and lumefantrine. This work
provides an analysis of molecular markers of drug
resistance to SP and other anti-malarials in isolates from
several sites across Afghanistan.
Methods
Blood samples were obtained from patients presenting
between July 2007 and February 2010 at malaria control
centres in the provinces (towns) of Nangarhar (Jalalabad),
Kunar (Asadabad), Faryab (Maimaneh) and Takhar
(Taloqan). The patients were adults and children over
six months old presenting with symptomatic, uncom-
plicated, microscopically confirmed mono-infection
with asexual stages of P. falciparum. Blood samples
were collected on filter paper (Whatman 3MM) at en-
rolment. Each filter paper was dried and individually
stored in a plastic bag containing silica gel. All filter
papers were subsequently transported to the Faculty of
Tropical Medicine, Mahidol University, Bangkok,
Thailand. Parasite DNA from dried blood spots was
extracted via the QIAmp DNA Mini kit using the
standard protocol and stored at −20°C until use. PCR-
RFLP directed at specific mutations in dhfr, dhps,
pfcrt, pfmdr1 as well as assessment of pfmdr1 copy
number was undertaken using previously described
techniques [11-14]; amplification was not always suc-
cessful, reflecting differing sensitivities of each PCR.In addition, samples with multiple mutations in dhps
(according to RFLP) were sequenced with the primer
corresponding to the published sequences R2 and R/
[11] to confirm multiple mutant genotypes. For the
purposes of analysis, in five samples where mixed
wild-type / mutant alleles were found at a single locus,
the allele was classified as mutant.
The study was approved by the Ethics Committee of
the Faculty of Tropical Medicine, Mahidol University,
Thailand, the Oxford Tropical Research Ethics Commit-
tee, Oxford University, UK and the Institutional Review
Board of the Afghan Public Health Institute, Ministry of
Public Health, Afghanistan. The work described was under-
taken within an overall framework of studies described at
the clinicaltrials.gov website under NCT00682578.
Results
A total of 120 samples were collected, involving 83
patients in Nangarhar, 22 in Kunar, 11 in Takhar and
four in Faryab provinces. Individual allele results are
shown in Table 1 and Figure 1. More than 90% of geno-
typed P. falciparum infections had a double mutation in
the dhfr gene (C59R, S108N). No mutations at dhfr posi-
tions 16, 51 or 164 were seen.
In the dhps gene, mutations were seen at A437 (7/57
isolates had 437 G and one isolate from Faryab province
had 437S), K540E (5/60) and A581G (8/60) (Figure 1A).
The dhps mutations were clearly linked when examining
haplotypes (Table 2), with K540E only seen when both
Figure 1 Prevalence of drug-resistance alleles in isolates of
Plasmodium falciparum obtained from Afghanistan in the years
2007–2010. A: SP resistance markers dhfr and dhps; B: relevant
pfmdr1 and pfcrt mutations. In all cases samples from the four
provinces of Afghanistan obtained in 2007 to 2010 are pooled.
Table 2 dhfr / dhps and pfmdr1 haplotypes
Genes Haplotype Number of isolates






ANRNI S – KAA 2
ANRNI S – KGA 1
ANRNI – – – – – 14
– – – – – SAKAA 27
– – – – – SGKGA 1
– – – – – SGEGA 3
pfmdr1 NYSND 16
NYSN – 9
NYS – – 2
NFSND 23
NFSN – 21
NFS – – 3
YFSND 2
YFSN – 3
– – SND 2
– – SN – 4
– – – – – 5
Haplotypes were determined by the allele at DHFR positions 16, 51, 59, 108
and 164, DHPS positions 436, 437, 540, 581 and 613 and PFMDR1 positions 86,
184, 1034, 1042 and 1246. Mutant alleles are indicated in bold.
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that seen in sulphadoxine-resistant parasites from
Southeast Asia [15,16]. Furthermore, all five isolates with
the triple dhps mutant haplotype were obtained in
eastern Afghanistan, being derived from Kunar (four iso-
lates) and Nangarhar (one isolate). The patients harbouring
these parasites were seen in late 2009 and treated with AS
+SP (three cases) and dihydroartemisinin-piperaquine (two
cases); all were followed to 42 days without experiencing
clinical or parasitological recurrence.
All isolates showed the pfcrt K76T mutation with no
mixed infections (Table 1, Figure 1B). Sequencing in a
subset of 28 isolates confirmed the SVNMT pfcrt haplo-
type, consistent with previous studies of pfcrt from
Afghanistan [17]. Five of 79 isolates had the pfmdr1
N86Y mutation, and 52/79 had pfmdr1 Y184F; positions
1034, 1042 and 1246 were wild type in all isolates. The
pfmdr1 gene was not amplified in any sample.Discussion
A regional overview of published dhfr and dhps marker
data from the last decade, including these new data from
Afghanistan along with published data obtained in Iran,
Pakistan and northern India (Table 3), reveals a broadly
consistent picture (Figure 2). Two mutations in dhfr
(C59R and S108N) are at or close to fixation throughout
the region, but few samples with triple mutations in dhfr
have been reported, and the critical dhfr I164L mutation
has remained extremely rare. dhps mutations have gen-
erally been found only in a minority of samples, and
generally as single mutations. However the A437G mu-
tation has been widespread for a considerable time, with
samples from southern [18] and north-western [19]
Pakistan showing mutation frequencies of 25 to 60%.
Previous work in south-east Iran has additionally de-
scribed relatively high numbers of isolates with S436A/F
[8]. From the perspective of combined mutations in dhfr
and dhps, quintuple mutant haplotypes have remained
very rare.
This study provides evidence for the presence of para-
sites with relatively higher levels of SP resistance in
Table 3 Published molecular surveys of sulphadoxine markers in south-western Asia








Khyber Pakhtunkhwa 5 [19] 2007
Khyber Pakhtunkhwa 6 [7] 2000–2003









Sistan and Baluchistan, Hormuzgan, Kerman 16 [24] 2000–2001
India
Rajasthan 17 [25] Not stated
Delhi 18 [26] 1995–2001
Figure 2 Regional prevalence of mutant alleles in dhfr and dhps. Proportions of isolates with mutations at five positions in dhfr (A16, N51,
C59, S108, I164) and dhps (S436, A437, K540E, A581, A613) are shown for all published molecular studies of SP resistance in south-western Asia
(including results described here). Data correspond to the publications described in Table 3, with cross-checking via the Molecular Surveyor
website of the Worldwide Anti-malarial Resistance Network (WWARN). Allele frequencies are shown as blue = wild-type, red = mutant,
white = not assessed.
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determined SP resistance may be close to compromising
the efficacy of first-line treatment for falciparum malaria
in Afghanistan. Development of this level of resistance
was presumably brought about by the long-term use of
SP in the region, since at the time of collection, artemisi-
nin combination therapy (AS+SP) had only just become
first-line treatment for falciparum malaria.
There are few data on the clinical response to AS+SP
in the setting of double dhfr and triple dhps mutations,
and relatively few patients documented as having this
haplotype have entered prospective clinical trials. It is
therefore difficult to predict the likely evolution of drug
resistance alleles in this area, and much may depend on
the field implementation of AS+SP. Unfortunately, there
is evidence that inappropriate anti-malarial regimens
continue to be prescribed in Afghanistan, including SP
alone [27]. This is likely to lead to a further worsening
of SP resistance, for example via mutations in dhfr (par-
ticularly I164L), and an AS+SP combination that in-
creasingly resembles artesunate monotherapy (with the
additional risk of emerging artemisinin resistance). In an
alternative scenario, consistent use of AS+SP holds the
potential to prevent an increase in (or even reduce) the
prevalence of SP-resistant parasites, in an analogous
manner to that seen for mefloquine [28] and generally
predicted for artemisinin combination partners [29].
This type of development was documented in south-east
Iran, where the introduction of AS+SP appears to have
prevented SP resistance from worsening, and led to a re-
duction in the proportion of parasites with the 437 G
dhps mutation [23]. Whatever the relative probabilities
of these two outcomes, ongoing studies examining
molecular markers as well as clinical efficacy, both in
Afghanistan and more widely across the region, are
urgently needed.
Conclusions
Molecular data reveal the presence in eastern Afghanistan
of P. falciparum parasites with higher levels of SP resistance
than previously documented in southern Asia. There is
no evidence yet that this is compromising the efficacy of
first-line treatment for falciparum malaria in Afghanistan
(AS+SP), but ongoing studies examining molecular markers
and clinical trials will continue to be important tools in
monitoring efficacy, both in Afghanistan and more widely
across the region.
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